Fort Lauderdale, Fla. — A team of France-based researchers has developed two new models of retinoblastoma for preclinical pharmacological testing as potential retinoblastoma therapies.
The study, presented at the ARVO 2011 Annual Meeting of the Association for Research in Vision and Ophthalmology this week, transplanted tumors into three groups of mice – two female SQUID mice and three male nude mice. Tumor cells developed in all injected eyes of two groups, and confirmed the retina, vitreous and anterior chamber had massive infiltration of retinoblastoma cells.
The researchers report, “Considering that our models well reproduce the patient’s tumor from which they have been obtained, these new orthotopic xenografts therefore offer new tools for relevant preclinical assessment.”
Abstract Title: Development Of New Models Of Orthotopic Primary Human Retinoblastoma Xenografts
Presentation Start/End Time: Monday, May 2, 2011; 1:45 – 2pm
Location: Room 114
Session Number: 249
# # #
The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include more than 12,500 eye and vision researchers from over 80 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology. For more information, visit www.arvo.org.
All abstracts accepted for presentation at the ARVO Annual Meeting represent previously unpublished data and conclusions. This research may be proprietary or may have been submitted for journal publication. Embargo policy: Journalists must seek approval from the presenter(s) before reporting data from paper or poster presentations. Press releases or stories on information presented at the ARVO Annual Meeting may not be released or published until the conclusion of the presentation.